Treatment Pathway of HR+/HER2- Metastatic Breast CA in England
Research type
Research Study
Full title
Treatment Pathway of HR+/HER2- Metastatic Breast Cancer in England
IRAS ID
280844
Contact name
John Were
Contact email
Sponsor organisation
Health iQ
Duration of Study in the UK
1 years, 1 months, 13 days
Research summary
Breast Cancer is an abnormal growth in the breast that tends to invade surrounding tissue and spread to other parts of the body. Being a debilitating disease, it is important to understand how much resources patients with breast cancer use up in the National Health Service, as well as the various treatments they undergo, and how those treatments impact their survival. This is especially true of metastatic breast cancer, or breast cancer that has spread to other parts of the body. This study aims to use pseudonymized data from Public Health England cancer and tumour registry (CAS) dataset to construct a group of patients with breast cancer. Using the same dataset linked to the cancer treatment datasets (systemic anticancer therapy or SACT, surgery in secondary care through the hospital episode statistics dataset or HES, radiotherapy through the radiotherapy dataset or RTDS), the study would determine treatment pathways. The span of time covered would be from 2012 to the latest available data when it would be requested. Once completed, this study would hopefully inform health policy to reconfigure services to provide better treatment pathways for patients.
REC name
London - Brent Research Ethics Committee
REC reference
20/LO/0627
Date of REC Opinion
3 Jul 2020
REC opinion
Favourable Opinion